Research Topics
Species | Antonio Maria RisitanoSummaryAffiliation: Federico II University Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAAAntonio Maria Risitano
Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Italy
Br J Haematol 148:791-6. 2010..Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures...- Immunosuppressive therapies in the management of acquired immune-mediated marrow failuresAntonio M Risitano
Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Naples, Italy
Curr Opin Hematol 19:3-13. 2012..Several attempts have been performed to improve the standard immunosuppression regimen of horse antithymocyte globulin (h-ATG) and cyclosporine A (CyA)... - In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencingAntonio M Risitano
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Lancet 364:355-64. 2004..In most cases, no obvious aetiological factor can be identified. However, clinical responses to immunosuppression strongly suggest an immune pathophysiology... - New challenges to developing animal models for human immune-mediated marrow failureAntonio M Risitano
Division of Hematology, Federico II University of Naples, Via Pansini 5, 80131 Naples, Italy
Clin Med Res 3:63-4. 2005 - Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromesAntonio M Risitano
Division of Hematology, Federico II University of Naples, Via Pansini 5, 80131 Naples, Italy
Curr Stem Cell Res Ther 2:39-52. 2007.... - Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumabAntonio M Risitano
Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
Blood 113:4094-100. 2009..Binding of C3 by PNH RBCs may constitute an additional disease mechanism in PNH, strongly enhanced by eculizumab treatment and producing a variable degree of extravascular hemolysis... - Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are goingAntonio M Risitano
Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Italy
Br J Haematol 152:127-40. 2011..Specific immunosuppressive strategies employed for other BMFS, such as lineage-restricted marrow failures, myelodysplastic syndromes and large granular lymphocyte leukaemia-associated cytopenias, are also briefly discussed... - Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3A M Risitano
Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
Mini Rev Med Chem 11:528-35. 2011..Finally, we provide a theoretical rationale for the development of novel strategies of complement inhibition which could in the future further improve on the already substantial efficacy of eculizumab... - Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patientsA M Risitano
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Leukemia 19:217-22. 2005.... - Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantationPatrizia Ricci
Department of Biochemistry and Medical Biotechnology, Hematology Branch, Federico II University of Naples, Naples, Italy
Transplantation 82:1449-56. 2006.... - Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumabC Selleri
Hemato Oncology Department, Medical School, University of Salerno, Italy
Mini Rev Med Chem 11:536-43. 2011..Even if the dose and the schedule may still require further refining, the available data support the need of large prospective trials comparing alemtuzumab to current standard IS regimens... - Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemiaMarcin W Wlodarski
Taussig Cancer Center/R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Blood 106:2769-80. 2005..In contrast, the physiologic clonal CTL repertoire is highly diverse and we were not able to detect any significant clonal sharing in 26 healthy controls... - Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responsesMagdalena Plasilova
Experimental Hematology and Hematopoiesis Section, and Hematopathology Section, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Immunol 172:1960-9. 2004.... - Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometryAntonio M Risitano
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Blood 100:178-83. 2002..As V beta skewing may correlate with relative V beta size, oligoclonality in combination with numerical V beta expansion can be applied to recognition of disease-specific T-cell receptors... - Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuriaJan Simak
Laboratory of Cellular Hematology, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
Br J Haematol 125:804-13. 2004..Analysis of circulating ECMP appears promising to provide useful information on the status of the vascular endothelium in PNH and SCD... - Shared and individual specificities of immunodominant cytotoxic T-cell clones in paroxysmal nocturnal hemoglobinuria as determined by molecular analysisMagdalena Plasilova
Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Exp Hematol 32:261-9. 2004..CONCLUSION: Analysis of the CDR3 sequence pattern as a marker for expanded immunodominant clonotypes may have an application in the study of T-cell responses in PNH... - Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalitiesElaine M Sloand
Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1652, USA
Blood 100:4427-32. 2002..Clinical data demonstrating the responsiveness of some patients with trisomy 8 to anti-thymocyte globulin (ATG) and cyclosporine (CsA) would favor an active role of the immune system in this syndrome... - Selective reduction of natural killer T cells in the bone marrow of aplastic anaemiaWeihua Zeng
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
Br J Haematol 119:803-9. 2002..These results show that NKT cells are profoundly decreased in AA and MDS, and their deficiency may, as in other human autoimmune diseases, play a role in the local immune dysregulation in AA and MDS... - CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrPc)Antonio M Risitano
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Exp Hematol 31:65-72. 2003..Conversely, PrP(c) is a good model to elucidate the fate of GPI-AP in PIG-A-deficient cells... - Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion proteinKarel Holada
Laboratory of Cellular Hematology, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
Blood 100:341-3. 2002..Our results indicate that in the absence of GPI anchor, PrPc can be expressed intracellularly and up-regulated on the platelet membrane, likely in a transmembrane form with the C-terminal part of the molecule inserted into the cytoplasm... - Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumabAntonio M Risitano
Blood 112:449-51. 2008 - Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndromeElaine M Sloand
Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10, Rm 7C108, National Institutes of Health, Bethesda, MD 20892, USA
Blood 106:841-51. 2005..An increased number of T cells with apparent specificity for trisomy 8 cells is consistent with an autoimmune pathophysiology in trisomy 8 MDS... - Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaRobert A Brodsky
Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
Blood 111:1840-7. 2008..This trial is registered at http://clinicaltrials.gov as NCT00130000... - Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen
Leeds General Infirmary, Leeds, United Kingdom
Blood 110:4123-8. 2007..001). These results show that eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH. This study is registered at http://clinicaltrials.gov (study ID no. NCT00122317)... - The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuriaPeter Hillmen
Leeds General Infirmary, Leeds, United Kingdom
N Engl J Med 355:1233-43. 2006..We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH)... - Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patientsWeihua Zeng
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Exp Hematol 32:806-14. 2004..A variety of cytokines and chemokines active in pathophysiologic cells likely play important roles in the recruitment and activation of lymphocytes to cytotoxic effectors for marrow hematopoietic target cells in AA... - Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimensHoon Kook
Hematology Branch of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Blood 99:3668-75. 2002..Our data indicate that multiple specific clones mediate the immune process in AA...